2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis;Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis

Reumatologia Clinica

Volumn 7, Issue 6, 2011, Pages 357-379

  Pérez Edo, Lluís ^a   Alonso Ruiz, Alberto ^b   Roig Vilaseca, Daniel ^c   García Vadillo, Alberto ^d   Guañabens Gay, Nuria ^e   Peris, Pilar ^e   Torrijos Eslava, Antonio ^f   Beltrán Audera, Chesús ^g   Fiter Aresté, Jordi ^h   Arboleya Rodríguez, Luis ⁱ   Graña Gil, Jenaro ^j   Carbonell Abelló, Jordi ^a   Nolla, Joan Miquel ^e   Holgado Pérez, Susana ^k   Salas Heredia, Esteban ^l   Zubieta Tabernero, Jaime ^m   Del Pino Montes, Javier ⁿ   Blanch i Rubió, Josep ^a   Caamaño Freire, Manuel ^o   Rodríguez Pérez, Manuel ^p   Castañeda, Santos ^d   Cerdá, Dacia ^e   Gómez Vaquero, Carmen ^e   Calvo Catalá, Javier ^q   Ciria, Manelestibaliz ^a   Loza, Estíbaliz ^r   more..

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c Unidad de Cuidados Intensivos Hospital Sant Joan Despi Moisés Broggi   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL MARINA BAIXA   (Spain)

^m HOSPITAL VIRGEN DE LA SALUD   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^o HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^p HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^q HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^r UNIDAD DE INVESTIGACIÓN   (Spain)

more..

Author keywords

Consensus; Guidelines; Osteoporosis; Recommendations

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BAZEDOXIFENE; CALCITONIN; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMENORRHEA; AMNESIA; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; BREAST CANCER; BREAST DISCHARGE; CALCIUM INTAKE; CATARACT; CELLULITIS; CHOLESTATIC HEPATITIS; COGNITIVE DEFECT; COMMON COLD; CONJUNCTIVITIS; CONSENSUS DEVELOPMENT; CONSTIPATION; CONVULSION; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DERMATITIS; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DIVERTICULITIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUODENITIS; DYSGEUSIA; DYSMENORRHEA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ECZEMA; EDEMA; EMPHYSEMA; ENDOMETRIUM HYPERPLASIA; EPISCLERITIS; EPISTAXIS; ESOPHAGITIS; ESOPHAGUS STENOSIS; ESOPHAGUS ULCER; EXERCISE; FATIGUE; FEMUR FRACTURE; FEVER; FLATULENCE; FLUSHING; FRACTURE IMMOBILIZATION; FRAGILITY FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GLOSSITIS; GLUCOSE INTOLERANCE; GYNECOMASTIA; HEADACHE; HEART ATRIUM FIBRILLATION; HEART MURMUR; HEART PALPITATION; HEMORRHOID; HIP FRACTURE; HIRSUTISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOTENSION; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INSOMNIA; IRITIS; ISCHIALGIA; JAUNDICE; KYPHOPLASTY; KYPHOSIS; LEG CRAMP; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; LIMB PAIN; LIVER FUNCTION TEST; LUNG EMBOLISM; MASTALGIA; MEDICAL SOCIETY; MENOPAUSE; MIGRAINE; MUCOSAL DRYNESS; MUSCLE CRAMP; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NOSE IRRITATION; OSTEOLYSIS; OTITIS; OVARY CANCER; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PAROSMIA; PERCUTANEOUS VERTEBROPLASTY; PERIPHERAL EDEMA; PHARYNGITIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RASH; RESPIRATORY TRACT INFECTION; RHINITIS; RISK FACTOR; SIDE EFFECT; SINUSITIS; SPINE RADIOGRAPHY; STROKE; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; URINARY TRACT INFECTION; URTICARIA; UVEITIS; VAGINA BLEEDING; VAGINITIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VERTIGO; VITAMIN INTAKE; VOMITING; WEIGHT GAIN;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SPAIN;

EID: 83555176125     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.05.013     Document Type: Article

References (267)

1. CEBM CfEBM. Oxford Centre for Evidence-based Medicine -Levels of Evidence (March 2009). 2009 [actualizado Marzo 2009; citado 2 Nov 2009]. Disponible en: http://www.cebm.net/index.aspx%3Fo=1025.
2. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy.
3. National Osteoporosis Guideline Group. NOGG. Sheffield: World Health Organization Collaborating Centre for Metabolic Bone Diseases; 2010 [actualizado Enero 2010; citado Marzo 2011]. Disponible en: http://www.shef.ac.uk/NOGG/.
4. Robinson C.M., Royds M., Abraham A., McQueen M.M., Court-Brown C.M., Christie J. Refractures in patients at least forty-five years old. a prospective analysis of twenty-two thousand and sixty patients. J Bone Joint Surg Am 2002, 84-A:1528-1533.
5. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis 1998, World Health Organization.
6. Melton L.J., Thamer M., Ray N.F., Chan J.K., Chesnut C.H., Einhorn T.A., et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12:16-23.
7. Brown J.P., Josse R.G. 2002 clinical practice guidelines for the diagnosis and Management of osteoporosis in Canada. CMAJ 2002, 167(Suppl 10):S1-S34.
8. Scottish Intercollegiate Guidelines Network [actualizado Mayo 2011; citado Mayo 2011]. Disponible en: http://www.sign.ac.uk/.
9. Melton L.J. How many women have osteoporosis now?. J Bone Miner Res 1995, 10:175-177.
10. Herrera A., Cáceres E., Caeiro J.R., Canales V., Curto J.M., Fernández N., et al. Recomendaciones de manejo clínico del paciente mayor de 50 años con fractura osteoporótica. REEMO 2003, 12:125-128.
11. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
12. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
13. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929-1936.
14. Kanterewicz E. Anamnesis. Exploración física. Estudio analítico. Manual de enfermedades óseas Sociedad Española de Reumatología 2010, 65-70. Editorial Médica Panamericana, Madrid. L. Arboleya, L. Pérez (Eds.).
15. Cooper C., O'Neill T., Silman A. The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 1993, 14(Suppl 1):S89-S97.
16. De Laet C., Kanis J.A., Oden A., Johanson H., Johnell O., Delmas P., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005, 16:1330-1338.
17. Brown J.P., Fortier M. Canadian consensus conference on osteoporosis, 2006 Update. JOGC 2006, S95-S112.
18. Tannenbaum C., Clark J., Schwartzman K., Wallenstein S., Lapinski R., Meier D., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002, 87:4431-4437.
19. Cerda Gabaroi D., Peris P., Monegal A., Albaladejo C., Martinez M.A., Muxi A., et al. Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 2010, 17:135-139.
20. Eastell R., Hannon R.A. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 2008, 67:157-162.
21. Garnero P. Bone markers in osteoporosis. Curr Osteoporos Rep 2009, 7:84-90.
22. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl 6):S2-S17.
23. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006, 22:61-66.
24. Diez-Perez A., Gonzalez-Macias J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 2008, 19:1511-1516.
25. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
26. Naves M., Diaz-Lopez J.B., Gomez C., Rodriguez-Rebollar A., Rodriguez-Garcia M., Cannata-Andia J.B. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int 2003, 14:520-524.
27. Naves M., Diaz-Lopez J.B., Gomez C., Rodriguez-Rebollar A., Cannata-Andia J.B. Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. Osteoporos Int 2005, 16:2013-2017.
28. Kanis J.A., Borgstrom F., De Laet C., Johansson H., Johnell O., Jonsson B., et al. Assessment of fracture risk. Osteoporos Int 2005, 16:581-589.
29. Hasserius R., Karlsson M.K., Nilsson B.E., Redlund-Johnell I., Johnell O. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003, 14:61-68.
30. Grados F., Fechtenbaum J., Flipon E., Kolta S., Roux C., Fardellone P. Radiographic methods for evaluating osteoporotic vertebral fractures. Joint Bone Spine 2009, 76:241-247.
31. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2010 [actualizado 2010; citado Mayo 2011]. Disponble en: http://www.ahrq.gov/clinic/uspstfix.htm.
32. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. 2008 [actualizado 2008; citado Abril 2011]. Disponible en: http://www.nof.org/.
33. International Society for Clinical Densitometry (ISCD). Canadian Physician pocket guide to BMD testing. 2004 [actualizado 2004; citado Abril 2011]. Disponible en: http://www.iscd.org/Visitors/PDFs/ISCD-CANADIANPanelOfficialPositions-BMDcard.pdf.
34. Lewiecki E.M., Baim S., Langman C.B., Bilezikian J.P. The official positions of the International Society for Clinical Densitometry: perceptions and commentary. J Clin Densitom 2009, 12:267-271.
35. Documento de Consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica. Reumatol Clin 2007, 3(Suppl 1):26-32. Panel de expertos del Documento de Consenso 2006 de la SER sobre la osteoporosis posmenopáusica.
36. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
37. González Macías J., Guañabens Gay N., Gómez Alonso C., Del Río Barquero L., Muñoz Torres M., Delgado M., et al. Guías de práctica clínica en la osteoporosis postmenopáuisca, glucocorticoidea y del varón. Sociedad Española de Investigación ósea y del Metabolismo Mineral. Rev Clin Esp 2008, 28(Suppl 1):1-24.
38. Kanis J.A., Melton L.J., Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
39. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395-1408.
40. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Strom O., Borgstrom F. Development and use of FRAX in osteoporosis. Osteoporos Int 2010, 21(Suppl 2):S407-S413.
41. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4:368-381.
42. Kanis J.A., Gluer C.C. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000, 11:192-202.
43. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
44. Stone K.L., Seeley D.G., Lui L.Y., Cauley J.A., Ensrud K., Browner W.S., et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003, 18:1947-1954.
45. Schuit S.C., Van der Klift M., Weel A.E., De Laet C.E., Burger H., Seeman E., et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004, 34:195-202.
46. Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., Delmas P., et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005, 20:1185-1194.
47. Cummings S.R., Cawthon P.M., Ensrud K.E., Cauley J.A., Fink H.A., Orwoll E.S. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006, 21:1550-1556.
48. Leslie W.D., Tsang J.F., Caetano P.A., Lix L.M. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 2007, 92:77-81.
49. Nelson H.D., Haney E.M., Dana T., Bougatsos C., Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010, 153:99-111.
50. Hans D., Downs R.W., Duboeuf F., Greenspan S., Jankowski L.G., Kiebzak G.M., et al. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom 2006, 9:15-21.
51. Baim S., Binkley N., Bilezikian J.P., Kendler D.L., Hans D.B., Lewiecki E.M., et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008, 11:75-91.
52. Hans D.B., Shepherd J.A., Schwartz E.N., Reid D.M., Blake G.M., Fordham J.N., et al. Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11:188-206.
53. Baim S., Wilson C.R., Lewiecki E.M., Luckey M.M., Downs R.W., Lentle B.C. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 2005, 8:371-378.
54. Lewiecki E.M., Binkley N., Petak S.M. DXA quality matters. J Clin Densitom 2006, 9:388-392.
55. Bell K.J., Hayen A., Macaskill P., Irwig L., Craig J.C., Ensrud K., et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 2009, 338:b2266.
56. Krieg M.A., Barkmann R., Gonnelli S., Stewart A., Bauer D.C., Del Rio Barquero L., et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11:163-187.
57. Nayak S., Olkin I., Liu H., Grabe M., Gould M.K., Allen I.E., et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med 2006, 144:832-841.
58. Engelke K., Adams J.E., Armbrecht G., Augat P., Bogado C.E., Bouxsein M.L., et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11:123-162.
59. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
60. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J., Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008, 42:467-475.
61. WHO Scientific Group. Assessment of osteoporosis at the primary health care level Geneva (Switzerland). World Health Organization; 2007 [actualizado 2007; citado Mayo 2011]. Disponible en: http://www.who.int/chp/topics/Osteoporosis.pdf.
62. Hind K., Burrows M. Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials. Bone 2007, 40:14-27.
63. Rizzoli R., Bianchi M.L., Garabedian M., McKay H.A., Moreno L.A. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone 2010, 46:294-305.
64. Chevalley T., Rizzoli R., Hans D., Ferrari S., Bonjour J.P. Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche. J Clin Endocrinol Metab 2005, 90:44-51.
65. Rowlands A.V., Ingledew D.K., Powell S.M., Eston R.G. Interactive effects of habitual physical activity and calcium intake on bone density in boys and girls. J Appl Physiol 2004, 97:1203-1208.
66. Chevalley T., Bonjour J.P., Ferrari S., Rizzoli R. High-protein intake enhances the positive impact of physical activity on BMC in prepubertal boys. J Bone Miner Res 2008, 23:131-142.
67. Martyn-St James M., Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab 2010, 28:251-267.
68. Bonaiuti D., Shea B., Iovine R., Negrini S., Robinson V., Kemper H.C., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002, CD000333.
69. Korpelainen R., Keinanen-Kiukaanniemi S., Heikkinen J., Vaananen K., Korpelainen J. Effect of impact exercise on bone mineral density in elderly women with low BMD: a population-based randomized controlled 30-month intervention. Osteoporos Int 2006, 17:109-118.
70. Sherrington C., Whitney J.C., Lord S.R., Herbert R.D., Cumming R.G., Close J.C. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 2008, 56:2234-2243.
71. Shea B., Wells G., Cranney A., Zytaruk N., Robinson V., Griffith L., et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002, 23:552-559.
72. Prince R.L., Devine A., Dhaliwal S.S., Dick I.M. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006, 166:869-875.
73. Bischoff-Ferrari H.A., Dawson-Hughes B., Baron J.A., Burckhardt P., Li R., Spiegelman D., et al. Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 2007, 86:1780-1790.
74. Bolland M.J., Barber P.A., Doughty R.N., Mason B., Horne A., Ames R., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336:262-266.
75. Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
76. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
77. Tang B.M., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370:657-666.
78. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Stuck A.E., Staehelin H.B., Orav E.J., et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169:551-561.
79. Sanders K.M., Stuart A.L., Williamson E.J., Simpson J.A., Kotowicz M.A., Young D., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:1815-1822.
80. Avenell A., Gillespie W.J., Gillespie L.D., O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009, CD000227.
81. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009, 339:b3692.
82. Gillespie L.D., Robertson M.C., Gillespie W.J., Lamb S.E., Gates S., Cumming R.G., et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009, CD007146.
83. Parker M.J., Gillespie W.J., Gillespie L.D. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006, 332:571-574.
84. Robinovitch S.N., Evans S.L., Minns J., Laing A.C., Kannus P., Cripton P.A., et al. Hip protectors: recommendations for biomechanical testing--an international consensus statement (part I). Osteoporos Int 2009, 20:1977-1988.
85. Cameron I.D., Robinovitch S., Birge S., Kannus P., Khan K., Lauritzen J., et al. Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II). Osteoporos Int 2010, 21:1-10.
86. Agulnek A.N., O'Leary K.J., Edwards B.J. Acute vertebral fracture. J Hosp Med 2009, 4:E20-E24.
87. Sheon RP, Rosen H. Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fracture [citado Mayo 2011]. Disponible en: http://www.uptodate.com/online/content/topic.do%3FtopicKey=spinaldi/6255%26selectedTitle=1%257E114%26source=search_result.
88. Mazanec D.J., Podichetty V.K., Mompoint A., Potnis A. Vertebral compression fractures: manage aggressively to prevent sequelae. Cleve Clin J Med 2003, 70:147-156.
89. Stadhouder A., Buskens E., Vergroesen D.A., Fidler M.W., De Nies F., Oner F.C. Nonoperative treatment of thoracic and lumbar spine fractures: a prospective randomized study of different treatment options. J Orthop Trauma 2009, 23:588-594.
90. Francis R.M., Aspray T.J., Hide G., Sutcliffe A.M., Wilkinson P. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008, 19:895-903.
91. Rousing R., Andersen M.O., Jespersen S.M., Thomsen K., Lauritsen J. Percutaneous vertebroplasty compared to conservative treatment in patients with painful acute or subacute osteoporotic vertebral fractures: three-months follow-up in a clinical randomized study. Spine (Phila Pa 1976) 2009, 34:1349-1354.
92. Wardlaw D., Cummings S.R., Van Meirhaeghe J., Bastian L., Tillman J.B., Ranstam J., et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet 2009, 373:1016-1024.
93. Voormolen M.H., Mali W.P., Lohle P.N., Fransen H., Lampmann L.E., Van der Graaf Y., et al. Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study. AJNR Am J Neuroradiol 2007, 28:555-560.
94. Kasperk C., Hillmeier J., Noldge G., Grafe I.A., Dafonseca K., Raupp D., et al. Treatment of painful vertebral fractures by kyphoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study. J Bone Miner Res 2005, 20:604-612.
95. Diamond T.H., Bryant C., Browne L., Clark W.A. Clinical outcomes after acute osteoporotic vertebral fractures: a 2-year non-randomised trial comparing percutaneous vertebroplasty with conservative therapy. Med J Aust 2006, 184:113-117.
96. Alvarez L., Alcaraz M., Perez-Higueras A., Granizo J.J., De Miguel I., Rossi R.E., et al. Percutaneous vertebroplasty: functional improvement in patients with osteoporotic compression fractures. Spine (Phila Pa 1976) 2006, 31:1113-1118.
97. Kallmes D.F., Comstock B.A., Heagerty P.J., Turner J.A., Wilson D.J., Diamond T.H., et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009, 361:569-579.
98. Buchbinder R., Osborne R.H., Ebeling P.R., Wark J.D., Mitchell P., Wriedt C., et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009, 361:557-568.
99. Klazen C.A., Lohle P.N., De Vries J., Jansen F.H., Tielbeek A.V., Blonk M.C., et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet 2010, 376:1085-1092.
100. Pérez-Nuñez M.I., Riancho del Corral J.A. Vertebroplastia y cifoplastia como tratamiento de las fracturas vertebrales osteoporóticas. Rev Osteopor Metab Miner 2010, 2:27-33.
101. Hosking D.J., Geusens P., Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM 2005, 98:403-413.
102. Riggs B.L., Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005, 20:177-184.
103. Lufkin E.G., Wahner H.W., O'Fallon W.M., Hodgson S.F., Kotowicz M.A., Lane A.W., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1-9.
104. Greenspan S.L., Resnick N.M., Parker R.A. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003, 289:2525-2533.
105. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
106. Overgaard K., Riis B.J., Christiansen C., Hansen M.A. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989, 299:477-479.
107. Chesnut C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267-276.
108. Lyritis G.P., Paspati I., Karachalios T., Ioakimidis D., Skarantavos G., Lyritis P.G. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997, 275:112-114.
109. Johnell O., Scheele W.H., Lu Y., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:985-992.
110. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., Adachi J., et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:524-528.
111. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
112. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
113. Adomaityte J., Farooq M., Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008, 99:338-342.
114. Barrett-Connor E., Cox D.A., Song J., Mitlak B., Mosca L., Grady D. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 2009, 122:754-761.
115. De Villiers T.J., Chines A.A., Palacios S., Lips P., Sawicki A.Z., Levine A.B., et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011, 22:567-576.
116. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., De Villiers T.J., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23:1923-1934.
117. Siris E.S., Pasquale M.K., Wang Y., Watts N.B. Estimating bisphosphonate use and fracture reduction among U.S. women age 45 and older, 2001-2008. J Bone Miner Res 2011, 26:3-11.
118. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, CD003376.
119. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, CD001155.
120. Cranney A., Wells G.A., Yetisir E., Adami S., Cooper C., Delmas P.D., et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009, 20:291-297.
121. Jansen J.P., Bergman G.J., Huels J., Olson M. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 2009, 25:1861-1868.
122. Cotte F.E., Fardellone P., Mercier F., Gaudin A.F., Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010, 21:145-155.
123. Arboleya L. Bisfosfonatos. Manual de enfermedades óseas de la SER 2010, Editorial Médica Panamericana, Madrid, p. 319-30.
124. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73-79.
125. Harris S.T., Watts N.B., Jackson R.D., Genant H.K., Wasnich R.D., Ross P., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993, 95:557-567.
126. Ott S.M., Woodson G.C., Huffer W.E., Miller P.D., Watts N.B. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 1994, 78:968-972.
127. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
128. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
129. Dansereau R.J., Crail D.J., Perkins A.C. In vitro disintegration studies of weekly generic alendronate sodium tablets (70mg) available in the US. Curr Med Res Opin 2009, 25:449-452.
130. Perkins A.C., Blackshaw P.E., Hay P.D., Lawes S.C., Atherton C.T., Dansereau R.J., et al. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 2008, 30:834-844.
131. Ringe J.D., Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009, 30:213-221.
132. Body J.J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.P., Goemaere S., et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010, 21:1657-1680.
133. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
134. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
135. Watts N.B., Josse R.G., Hamdy R.C., Hughes R.A., Manhart M.D., Barton I., et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003, 88:542-549.
136. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 74:129-135.
137. Cranney A., Tugwell P., Adachi J., Weaver B., Zytaruk N., Papaioannou A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517-523.
138. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103-111.
139. Chesnut I.C., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
140. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
141. Stakkestad J.A., Lakatos P., Lorenc R., Sedarati F., Neate C., Reginster J.Y. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008, 27:955-960.
142. Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008, 24:237-245.
143. Sebba A.I., Emkey R.D., Kohles J.D., Sambrook P.N. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 2009, 44:423-427.
144. Harris S.T., Reginster J.Y., Harley C., Blumentals W.A., Poston S.A., Barr C.E., et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009, 44:758-765.
145. Delmas P.D., Adami S., Strugala C., Stakkestad J.A., Reginster J.Y., Felsenberg D., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006, 54:1838-1846.
146. Von Moos R., Caspar C.B., Thurlimann B., Angst R., Inauen R., Greil R., et al. Renal safety profiles of ibandronate 6mg infused over 15 and 60min: a randomized, open-label study. Ann Oncol 2008, 19:1266-1270.
147. Boonen S., Vanderschueren D., Venken K., Milisen K., Delforge M., Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 2008, 264:315-332.
148. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
149. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
150. Colon-Emeric C.S., Mesenbrink P., Lyles K.W., Pieper C.F., Boonen S., Delmas P., et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010, 25:91-97.
151. Arboleya L., Alperi M., Alonso S. Efectos adversos de los bisfosfonatos. Reumatol Clin 2011, 7:189-197.
152. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010, 86:421-435.
153. Edwards B.J., Gounder M., McKoy J.M., Boyd I., Farrugia M., Migliorati C., et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008, 9:1166-1172.
154. Agencia Española del Medicamento y productos Sanitarios. Nota informativa de la AEMPS: Recomendaciones para la prevención de la osteonecrosis del maxilar asociada al tratamiento con bisfosfonatos. 2009 [actualizado 2009; citado 2010]. Disponible en: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/NI_2009-10_bisfosfonatos.htm.
155. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65:2397-2410.
156. Baim S., Miller P.D. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009, 24:561-574.
157. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
158. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
159. Koh J.S., Goh S.K., Png M.A., Kwek E.B., Howe T.S. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J Orthop Trauma 2010, 24:75-81.
160. Pazianas M., Cooper C., Ebetino F.H., Russell R.G. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010, 6:325-343.
161. Rheumatology ACo. Denosumab. 2010 [actualizado Octubre 2010; citado Abril 2011]. Disponible en: http://www.rheumatology.org/publications/hotline/2010_10_18_denosumab.asp.
162. Lewiecki E.M. Denosumab update. Curr Opin Rheumatol 2009, 21:369-373.
163. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
164. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
165. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
166. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
167. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., De Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
168. Seeman E., Delmas P.D., Hanley D.A., Sellmeyer D., Cheung A.M., Shane E., et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
169. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
170. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
171. Genant H.K., Engelke K., Hanley D.A., Brown J.P., Omizo M., Bone H.G., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
172. Reid I.R., Miller P.D., Brown J.P., Kendler D.L., Fahrleitner-Pammer A., Valter I., et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25:2256-2265.
173. Tam C.S., Heersche J.N., Murray T.M., Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982, 110:506-512.
174. Hock J.M., Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992, 7:65-72.
175. Whitfield J., Morley P., Willick G. The parathyroid hormone, its fragments and analogues--potent bone-builders for treating osteoporosis. Expert Opin Investig Drugs 2000, 9:1293-1315.
176. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001, 142:4047-4054.
177. European Medicines Agency. Forsteo. 2010 [actualizado 2010; citado Mayo 2011]. Disponible en: http://www.emea.eu.int/humandocs/humans/EPAR/forsteo.
178. Schwietert H.R., Groen E.W., Sollie F.A., Jonkman J.H. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997, 61:360-376.
179. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
180. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
181. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
182. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146:326-339.
183. Body J.J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528-4535.
184. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
185. Guías de práctica clínica en la osteoporosis postmenopáusica glucocorticoidea y del varón. Rev Clin Esp 2008, 8(Supl 1):1-24. SEIOMM.
186. Guías de práctica clínica en la osteoporosis postmenopáusica glucocorticoidea y del varón. Rev Osteoporos Metab Miner 2009, 1:53-60. SEIOMM.
187. Jolette J., Wilker C.E., Smith S.Y., Doyle N., Hardisty J.F., Metcalfe A.J., et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006, 34:929-940.
188. Tashjian A.H., Chabner B.A. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002, 17:1151-1161.
189. Subbiah V., Madsen V.S., Raymond A.K., Benjamin R.S., Ludwig J.A. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 2010, 21:1041-1045.
190. Peris P. Toxicidad de la teriparatida. Rev Esp Reum 2004, 3:19-23.
191. Bevilacqua M., Dominguez L., Chebat E., Barrella M., Righini V., Gandolini G., et al. Teriparatide (1-34) vs. Parathyroid Hormone (1-84) in Women with Severe Postmenopausal Osteoporosis: a Randomized, Head-to-head Study. ASBMR 30th Annual Meeting; 2008; Montréal 2008, 48.
192. Piemonte S., Romagnoli E., Cipriani C., Fassino V., Del Fiacco R., Carnevale V., et al. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study. Calcif Tissue Int 2009, 85:287-292.
193. Marie P.J., Hott M., Modrowski D., De Pollak C., Guillemain J., Deloffre P., et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8:607-615.
194. Chattopadhyay N., Quinn S.J., Kifor O., Ye C., Brown E.M. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 2007, 74:438-447.
195. Caverzasio J. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone 2008, 42:1131-1136.
196. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
197. Meunier P.J., Reginster J.Y. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003, 14(Suppl 3):S66-S76.
198. Reginster J.Y., Felsenberg D., Boonen S., Diez-Perez A., Rizzoli R., Brandi M.L., et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:1687-1695.
199. Reginster J.Y., Bruyere O., Sawicki A., Roces-Varela A., Fardellone P., Roberts A., et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009, 45:1059-1064.
200. Breart G., Cooper C., Meyer O., Speirs C., Deltour N., Reginster J.Y. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010, 21:1181-1187.
201. Jonville-Bera A.P., Crickx B., Aaron L., Hartingh I., Autret-Leca E. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy 2009, 64:658-659.
202. Pernicova I., Middleton E.T., Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 2008, 19:1811-1812.
203. Grosso A., Douglas I., Hingorani A., MacAllister R., Smeeth L. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008, 66:689-694.
204. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25:937-947.
205. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26:242-251.
206. Stroup G.B., Kumar S., Jerome C.P. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 2009, 85:344-355.
207. Isabel E., Bateman K.P., Chauret N., Cromlish W., Desmarais S., Duong le T., et al. The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. Bioorg Med Chem Lett 2010, 20:887-892.
208. Murphy M.G., Cerchio K., Stoch S.A., Gottesdiener K., Wu M., Recker R. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005, 90:2022-2028.
209. Hannon R.A., Clack G., Rimmer M., Swaisland A., Lockton J.A., Finkelman R.D., et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 2010, 25:463-471.
210. Schaller S., Henriksen K., Sveigaard C., Heegaard A.M., Helix N., Stahlhut M., et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004, 19:1144-1153.
211. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
212. Li X., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., Grisanti M., et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male rats. J Bone Miner Res 2010, 25:2647-2656.
213. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
214. Bodine P.V., Stauffer B., Ponce-de-Leon H., Bhat R.A., Mangine A., Seestaller-Wehr L.M., et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 2009, 44:1063-1068.
215. Lotinun S., Pearsall R.S., Davies M.V., Marvell T.H., Monnell T.E., Ucran J., et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010, 46:1082-1088.
216. Fajardo R.J., Manoharan R.K., Pearsall R.S., Davies M.V., Marvell T., Monnell T.E., et al. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 2010, 46:64-71.
217. Ruckle J., Jacobs M., Kramer W., Pearsall A.E., Kumar R., Underwood K.W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009, 24:744-752.
218. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
219. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
220. Deal C., Omizo M., Schwartz E.N., Eriksen E.F., Cantor P., Wang J., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005, 20:1905-1911.
221. Ste-Marie L.G., Schwartz S.L., Hossain A., Desaiah D., Gaich G.A. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2006, 21:283-291.
222. Anastasilakis A.D., Polyzos S.A., Avramidis A., Papatheodorou A., Terpos E. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res 2009, 41:559-562.
223. Obermayer-Pietsch B.M., Marin F., McCloskey E.V., Hadji P., Farrerons J., Boonen S., et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008, 23:1591-1600.
224. Boonen S., Marin F., Obermayer-Pietsch B., Simoes M.E., Barker C., Glass E.V., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852-860.
225. Wimalawansa S.J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995, 99:36-42.
226. Lindsay R., Cosman F., Lobo R.A., Walsh B.W., Harris S.T., Reagan J.E., et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999, 84:3076-3081.
227. Harris S.T., Eriksen E.F., Davidson M., Ettinger M.P., Moffett A.H., Baylink D.J., et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001, 86:1890-1897.
228. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
229. Siris E.S., Harris S.T., Eastell R., Zanchetta J.R., Goemaere S., Diez-Perez A., et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005, 20:1514-1524.
230. Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol. 2010;29:1079-84.
231. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
232. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586-1592.
233. Chen P., Miller P.D., Delmas P.D., Misurski D.A., Krege J.H. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:1785-1790.
234. International Society for Clinical Densitometry (ISCD). 2007 ISCD Official Positions. Middletown; 2007 [actualizado 2007; citado Mayo 2011]. Disponible en: http://www.iscd.org/.
235. Delmas P.D., Vrijens B., Eastell R., Roux C., Pols H.A., Ringe J.D., et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007, 92:1296-1304.
236. Estudio de la densidad ósea en la población española 1992, Grupo de Trabajo en Osteoporosis (GTO), Edimsa, Madrid. R.-P. Rorer (Ed.).
237. Ciria M, Laiz A, Benito P. Osteoporosis y grado de conocimiento de la misma en la población española. En: Reumatología SEd, editor. Estudio EPISER Prevalencia e impacto de las enfermedades reumáticas en la población española. Madrid: Sociedad Española de Reumatología; 2001. p. 101-24.
238. Cannata J.B., Naves M.L., Virgós M.J., Gómez Alonso C., Díaz López J.B. Epidemiología de las fracturas vertebrales. Rev Esp Enf Metab Oseas 1993, 2(Supl B):2.
239. Olmos J.M., Martinez J., Garcia J., Matorras P., Moreno J.J., Gonzalez-Macias J. [Incidence of hip fractures in Cantabria]. Med Clin (Barc) 1992, 99:729-731.
240. Sosa M. La fractura osteoporótica de cadera en España. Rev Esp Enf Metab Oseas 1993, 2:189-192.
241. Peris P., Guanabens N., Monegal A., Suris X., Alvarez L., Martinez de Osaba M.J., et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol 1995, 34:936-941.
242. Peris P., Guanabens N. Male osteoporosis. Curr Opin Rheumatol 1996, 8:357-364.
243. Blanch J., Pacifici R., Benito P., Ciria M., Perez-Edo L., Pros A., et al. Osteoporosis in men. J Bone Min Res 1996, 11:S231.
244. Jackson J.A., Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore) 1990, 69:137-152.
245. Goldray D., Weisman Y., Jaccard N., Merdler C., Chen J., Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993, 76:288-290.
246. Morrison D., Capewell S., Reynolds S.P., Thomas J., Ali N.J., Read G.F., et al. Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med 1994, 88:659-663.
247. Zhong Z.M., Chen J.T. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Clin Drug Investig 2009, 29:349-357.
248. Orwoll E.S., Miller P.D., Adachi J.D., Brown J., Adler R.A., Kendler D., et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25:2239-2250.
249. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
250. Lewiecki E.M., Gordon C.M., Baim S., Leonard M.B., Bishop N.J., Bianchi M.L., et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008, 43:1115-1121.
251. Peris P., Guanabens N., Martinez de Osaba M.J., Monegal A., Alvarez L., Pons F., et al. Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum 2002, 32:64-70.
252. Bhalla A.K. Management of osteoporosis in a pre-menopausal woman. Best Pract Res Clin Rheumatol 2010, 24:313-327.
253. Peris P. Osteoporosis en individuos jóvenes. Reumatol Clin 2010, 6:217-223.
254. Van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
255. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
256. a ed. Barcelona: Amer Society For Bone & Mineral; 2007. p. 361-8.
257. Huizenga N.A., Koper J.W., De Lange, Pols H.A., Stolk R.P., Burguer H., et al. A polimorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998, 144-151.
258. Sosa Henriquez M., Díaz Curiel M., Díez Pérez A., Gómez Alonso C., González Macías J., Farrerons Minguella J., et al. Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna. Rev Clin Esp 2008, 208:33-45.
259. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292-299.
260. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., Laan R.F., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
261. Reid D.M., Devogelaer J.P., Saag K., Roux C., Lau C.S., Reginster J.Y., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
262. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
263. Sambrook P.N. Anabolic therapy in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2084-2086.
264. Silverman S.L., Lane N.E. Glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2009, 7:23-26.
265. Adler R.A. Glucocorticoid-induced osteoporosis: management update. Curr Osteoporos Rep 2010, 8:10-14.
266. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010, 6:82-88.
267. Condon J.R., Nassim I.R., Dent C.E., Hilb A., Staihorpe E.M. Possible prevention and treatment of steroid-induced osteoporosis. Postgrad Med J 1978, 54:249-252.